Shares of Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.06 and traded as high as $1.74. Cortexyme shares last traded at $1.71, with a volume of 141,555 shares traded.
Cortexyme Stock Up 10.3 %
The business’s 50-day simple moving average is $1.71 and its two-hundred day simple moving average is $1.07. The firm has a market capitalization of $58.19 million, a price-to-earnings ratio of -0.65 and a beta of 1.40.
About Cortexyme
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Further Reading
- Five stocks we like better than Cortexyme
- Stock Dividend Cuts Happen Are You Ready?
- Power Up: Gaming Industry Expansion Fuels Stock Opportunities
- What is a Dividend King?
- These 3 Quirky ETFs May Be Strong Plays in 2025
- Consumer Staples Stocks, Explained
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
